Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-01-04
Based on 637 first isolates · URO · Cystitis (lower UTI) · 2025-01-05 → 2026-01-04
Urology
Per-organism detail: URO urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 88 % (85 %–90 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (4 %), Pseudomonas aeruginosa (4 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
88 %
88 %
n = 34
meropenem MEM
trend · Escherichia coli reserve
83 %
79 %
n = 34
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
78 %
76 %
n = 34
mecillinam MEC
trend · Escherichia coli lower UTI only
76 %
68 %
n = 34
ciprofloxacin CIP
trend · Escherichia coli
72 %
68 %
n = 34
ceftriaxone CRO
trend · Escherichia coli
72 %
65 %
n = 34
65 %
59 %
n = 34
trimethoprim TMP
trend · Escherichia coli lower UTI only
64 %
53 %
n = 34
48 %
47 %
n = 34
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
21 %
n = 34
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
3 %
n = 34
3 %
6 %
n = 34

Most likely organisms for this profile

Escherichia coli
59 %
Enterococcus faecalis
11 %
Klebsiella pneumoniae
11 %
Proteus mirabilis
4 %
Staphylococcus aureus
4 %
Pseudomonas aeruginosa
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.